ReviewFrontiers in cellular and infection microbiology2026
Therapeutic modulation of the gut microbiota by traditional Chinese medicine in the management of cholestatic liver injury.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestatic liver injury (CLI) is a complex pathology characterized by impaired bile excretion and a lack of effective curative therapies. Emerging evidence indicates that the gut microbiota plays a critical role in the pathogenesis of CLI via the gut-liver axis. Specifically, gut dysbiosis disrupts bile acid homeostasis, triggers immune-mediated inflammation, exacerbates oxidative stress, and dysregulates multiple signaling pathways, thereby accelerating hepatic damage. Traditional Chinese Medicine (TCM) offers a distinct therapeutic advantage through its multi-component, multi-target mechanisms. Many studies have shown that TCM herbal extracts and some formulas can attenuate CLI by restructuring the gut microbiome. These interventions work by promoting beneficial bacterial proliferation, restoring intestinal barrier integrity, modulating bile acid receptors, and suppressing inflammation and fibrosis. This review synthesizes current mechanisms linking gut dysbiosis to CLI and evaluates recent advances in TCM-based strategies that target the gut microbiota, offering theoretical insights for novel clinical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.